65,437 trials
Leukemia
Primary: Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Major Cytogenetic Response (MCyR) — 50.8 Percentage of participants
Endotracheal Intubation · Supraglottic Airway
Primary: Time Required for Intubation — 21.04; 30.04 seconds — p=0.02
Hepatitis B
Primary: Number of Participants With an Adverse Event — 74 participants
MDS · Myelodysplastic Syndromes · Thrombocytopenia
Primary: Occurrence of a Clinically Significant Thrombocytopenic Event — 11; 8; 10; 11 Participants
Non-inflammatory Arthritis
Primary: Knee Society Passive Flexion at 6 Months — 124.2; 124.0 Degrees of passive flexion
Hepatitis
Primary: Number of Patients With Improvement in Liver Histology — 12 participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c at Week 80 — 8.64; 8.64; -1.36; -1.85 percent change — p=<0.0001
Anxiety · Anxiety Disorders · Anxiety Neuroses
Primary: Least Square Mean Change From Randomization to Week 8 in Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.74; -9.61 units on scale
Erectile Dysfunction
Primary: Area Under the Curve (AUC 0-t) — 1467.00; 1458.45; 1493.53 ng*hr/mL
Hypertrophic Scarring After Burn Injury
Primary: Pressure Under Compression Garment — 25; 6.4 mm Hg
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants
Head and Neck Cancer
Primary: Patient Response to Treatment — 1; 10; 10; 4 participants
Breast Cancer
Primary: Percentage of Participants Achieving Pathologic Complete Response (pCR) — 24.3; 25.2 Percentage of Participants — p=0.8921
Restless Legs Syndrome
Primary: Number of Participants With Any Adverse Event — 44 participants
Juvenile Rheumatoid Arthritis
Primary: Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16 — 23 Participants